Skip to main content
Erschienen in: Clinical & Experimental Metastasis 6/2011

01.08.2011 | Research Paper

Dickkopf-1 is frequently overexpressed in ovarian serous carcinoma and involved in tumor invasion

verfasst von: Shizhuo Wang, Shulan Zhang

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Abstract

Dickkopf-1 (DKK1) was known as a negative regulator of the Wnt signaling pathway, which played a crucial role in carcinogenesis. However, its function in human cancers remained elusive. In this study, we aimed to investigate the role of DKK1 in ovarian serous papillary adenocarcinoma (OSC) tumor progression and invasion. Quantitative real-time RT–PCR and Western blot analysis showed that the expression of DKK1 mRNA and protein in 32 OSC tissues were elevated as compared with those in 10 normal ovarian tissues (P = 0.005, P = 0.003, respectively). Immunohistochemical analysis in 178 clinical OSC samples showed that the expression of DKK1 was positively associated with FIGO stage (P = 0.016). Furthermore, the expression of DKK1 protein was positively associated with P-JNK1 protein expression in 178 OSC tissues. DKK1, P-JNK1 and the co-expression of DKK1 and P-JNK1 were all unfavorable prognosis factors for OSC patients (P < 0.0001). DKK1, alone or combined with P-JNK1, was an independent predictor for the 5 year survival (P = 0.015, P < 0.0001, respectively). DKK1 could promote OSC cells invasion and the growth of OSC nude mice xenograft. DKK1 in OSC cells could activate P-JNK1 expression and significantly promote formations of actin filaments and filopodia. Thus, DKK1, alone or combined with P-JNK1, was a novel prognostic predictor for OSC patients and contributed to the invasion of OSC.
Literatur
1.
Zurück zum Zitat Peifer M, Polakis P (2000) Wnt signaling in oncogenesis and embryogenesis—a look outside the nucleus. Science 287:1606–1609PubMedCrossRef Peifer M, Polakis P (2000) Wnt signaling in oncogenesis and embryogenesis—a look outside the nucleus. Science 287:1606–1609PubMedCrossRef
2.
Zurück zum Zitat Polakis P (2007) The many ways of Wnt in cancer. Curr Opin Genet Dev 7:45–51CrossRef Polakis P (2007) The many ways of Wnt in cancer. Curr Opin Genet Dev 7:45–51CrossRef
3.
Zurück zum Zitat Logan CY, Nusse R (2004) The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20:781–810PubMedCrossRef Logan CY, Nusse R (2004) The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20:781–810PubMedCrossRef
4.
Zurück zum Zitat Niehrs C (2006) Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 25:7469–7481PubMedCrossRef Niehrs C (2006) Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 25:7469–7481PubMedCrossRef
5.
Zurück zum Zitat Krupnik VE, Sharp JD, Jiang C et al (1999) Functional and structural diversity of the human Dickkopf gene family. Gene 238:301–313PubMedCrossRef Krupnik VE, Sharp JD, Jiang C et al (1999) Functional and structural diversity of the human Dickkopf gene family. Gene 238:301–313PubMedCrossRef
6.
Zurück zum Zitat Glinka A, Wu W, Delius H et al (1998) Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 391:357–362PubMedCrossRef Glinka A, Wu W, Delius H et al (1998) Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 391:357–362PubMedCrossRef
7.
Zurück zum Zitat Wu W, Glinka A, Delius H, Niehrs C (2000) Mutual antagonism between dickkopf1 and dickkopf2 regulates Wnt/beta-catenin signalling. Curr Biol 10:1611–1614PubMedCrossRef Wu W, Glinka A, Delius H, Niehrs C (2000) Mutual antagonism between dickkopf1 and dickkopf2 regulates Wnt/beta-catenin signalling. Curr Biol 10:1611–1614PubMedCrossRef
8.
Zurück zum Zitat Niida A, Hiroko T, Kasai M et al (2004) DKK1, a negative regulator of Wnt signaling, is a target of theβ-catenin/TCF pathway. Oncogene 23:8520–8526PubMedCrossRef Niida A, Hiroko T, Kasai M et al (2004) DKK1, a negative regulator of Wnt signaling, is a target of theβ-catenin/TCF pathway. Oncogene 23:8520–8526PubMedCrossRef
9.
Zurück zum Zitat Gonzalez-Sancho JM, Aguilera O, Garcia JM et al (2005) The Wnt antagonist DICKKOPF-1 gene is a downstream target of β-catenin/TCF and is downregulated in human colon cancer. Oncogene 24:1098–1103PubMedCrossRef Gonzalez-Sancho JM, Aguilera O, Garcia JM et al (2005) The Wnt antagonist DICKKOPF-1 gene is a downstream target of β-catenin/TCF and is downregulated in human colon cancer. Oncogene 24:1098–1103PubMedCrossRef
10.
Zurück zum Zitat Wirths O, Waha A, Weggen S et al (2003) Overexpression of human Dickkopf-1, an antagonist of wingless/WNT signaling, in human hepatoblastomas and Wilms’ tumors. Lab Invest 83:429–434PubMed Wirths O, Waha A, Weggen S et al (2003) Overexpression of human Dickkopf-1, an antagonist of wingless/WNT signaling, in human hepatoblastomas and Wilms’ tumors. Lab Invest 83:429–434PubMed
11.
Zurück zum Zitat Forget MA, Turcotte S, Beauseigle D et al (2007) The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types. Br J Cancer 96:646–653PubMedCrossRef Forget MA, Turcotte S, Beauseigle D et al (2007) The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types. Br J Cancer 96:646–653PubMedCrossRef
12.
Zurück zum Zitat Yamabuki T, Takano A, Hayama S et al (2007) Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res 67:2517–2525PubMedCrossRef Yamabuki T, Takano A, Hayama S et al (2007) Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res 67:2517–2525PubMedCrossRef
13.
Zurück zum Zitat Yu B, Yang X, Xu Y et al (2009) Elevated expression of DKK1 is associated with cytoplasmic/nuclear beta-catenin accumulation and poor prognosis in hepatocellular carcinomas. J Hepatol 50:948–957PubMedCrossRef Yu B, Yang X, Xu Y et al (2009) Elevated expression of DKK1 is associated with cytoplasmic/nuclear beta-catenin accumulation and poor prognosis in hepatocellular carcinomas. J Hepatol 50:948–957PubMedCrossRef
14.
Zurück zum Zitat Voorzanger-Rousselot N, Goehrig D, Journe F et al (2007) Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer 97:964–970PubMed Voorzanger-Rousselot N, Goehrig D, Journe F et al (2007) Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer 97:964–970PubMed
15.
Zurück zum Zitat Hall CL, Kang S, MacDougald OA et al (2006) Role of Wnts in prostate cancer bone metastases. J Cell Biochem 97:661–672PubMedCrossRef Hall CL, Kang S, MacDougald OA et al (2006) Role of Wnts in prostate cancer bone metastases. J Cell Biochem 97:661–672PubMedCrossRef
16.
Zurück zum Zitat Shizhuo W, Tao J, Shulan Z et al (2009) The expression and significance of Dickkopf-1 in epithelial ovarian carcinoma. Int J Biol Markers 24:165–170PubMed Shizhuo W, Tao J, Shulan Z et al (2009) The expression and significance of Dickkopf-1 in epithelial ovarian carcinoma. Int J Biol Markers 24:165–170PubMed
17.
Zurück zum Zitat Torres MP, Ponnusamy MP, Lakshmanan I et al (2009) Immunopathogenesis of ovarian cancer. Minerva Med 100:385–400PubMed Torres MP, Ponnusamy MP, Lakshmanan I et al (2009) Immunopathogenesis of ovarian cancer. Minerva Med 100:385–400PubMed
18.
Zurück zum Zitat Harrison ML, Jameson C, Gore ME (2008) Mucinous ovarian cancer. Int J Gynecol Cancer 18:209–214PubMedCrossRef Harrison ML, Jameson C, Gore ME (2008) Mucinous ovarian cancer. Int J Gynecol Cancer 18:209–214PubMedCrossRef
19.
Zurück zum Zitat Gómez-Raposo C, Mendiola M, Barriuso J et al (2010) Molecular characterization of ovarian cancer by gene-expression profiling. Gynecol Oncol 118:88–92PubMedCrossRef Gómez-Raposo C, Mendiola M, Barriuso J et al (2010) Molecular characterization of ovarian cancer by gene-expression profiling. Gynecol Oncol 118:88–92PubMedCrossRef
20.
Zurück zum Zitat Jarboe JS, Johnson KR, Choi Y et al (2007) Expression of interleukin-13 receptor α2 in glioblastoma multiforme: implications for targeted therapies. Cancer Res 67:7983–7986PubMedCrossRef Jarboe JS, Johnson KR, Choi Y et al (2007) Expression of interleukin-13 receptor α2 in glioblastoma multiforme: implications for targeted therapies. Cancer Res 67:7983–7986PubMedCrossRef
21.
Zurück zum Zitat Hao XP, Pretlow TG, Rao JS et al (2001) Beta-catenin expression is altered in human colonic aberrant crypt foci. Cancer Res 61:8085–8088PubMed Hao XP, Pretlow TG, Rao JS et al (2001) Beta-catenin expression is altered in human colonic aberrant crypt foci. Cancer Res 61:8085–8088PubMed
22.
Zurück zum Zitat Endo Y, Beauchamp E, Woods D et al (2008) Wnt-3a and Dickkopf-1 stimulate neurite outgrowth in Ewing tumor cells via a Frizzled3- and c-Jun N-terminal kinase-dependent mechanism. Mol Cell Biol 28:2368–2379PubMedCrossRef Endo Y, Beauchamp E, Woods D et al (2008) Wnt-3a and Dickkopf-1 stimulate neurite outgrowth in Ewing tumor cells via a Frizzled3- and c-Jun N-terminal kinase-dependent mechanism. Mol Cell Biol 28:2368–2379PubMedCrossRef
23.
Zurück zum Zitat Xia Y, Karin M (2004) The control of cell motility and epithelial morphogenesis by Jun kinases. Trends Cell Biol 14:10–94CrossRef Xia Y, Karin M (2004) The control of cell motility and epithelial morphogenesis by Jun kinases. Trends Cell Biol 14:10–94CrossRef
24.
Zurück zum Zitat Friedl P, Wolf K (2003) Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 3:362–374PubMedCrossRef Friedl P, Wolf K (2003) Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 3:362–374PubMedCrossRef
25.
Zurück zum Zitat Wang W, Goswami S, Lapidus K et al (2004) Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors. Cancer Res 64:8585–8594PubMedCrossRef Wang W, Goswami S, Lapidus K et al (2004) Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors. Cancer Res 64:8585–8594PubMedCrossRef
26.
Zurück zum Zitat Seoud M, Salem Z, Shamseddine A et al (1999) Papillary serous carcinoma of the ovary following prolonged tamoxifen treatment. Eur J Gynaecol Oncol 20:237–239PubMed Seoud M, Salem Z, Shamseddine A et al (1999) Papillary serous carcinoma of the ovary following prolonged tamoxifen treatment. Eur J Gynaecol Oncol 20:237–239PubMed
27.
Zurück zum Zitat Vivas-Mejia P, Benito JM, Fernandez A et al (2010) c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clin Cancer Res 16:184–194PubMedCrossRef Vivas-Mejia P, Benito JM, Fernandez A et al (2010) c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clin Cancer Res 16:184–194PubMedCrossRef
Metadaten
Titel
Dickkopf-1 is frequently overexpressed in ovarian serous carcinoma and involved in tumor invasion
verfasst von
Shizhuo Wang
Shulan Zhang
Publikationsdatum
01.08.2011
Verlag
Springer Netherlands
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 6/2011
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-011-9393-9

Weitere Artikel der Ausgabe 6/2011

Clinical & Experimental Metastasis 6/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.